Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
KURA Analyst Ratings
Strong Buy
10 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
KURA Stock 12 Month Forecast
Average Price Target
$24.70
▲(299.68% Upside)
| Highest Price Target$40.00 | Average Price Target$24.70 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
JMP Securities
Reiterated
04/09/25
LifeSci Capital
Reiterated
04/08/25
H.C. Wainwright
Reiterated
04/08/25
BTIG
Reiterated
02/27/25
Scotiabank
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Bank of America Securities
Reiterated
02/26/25
TD Cowen
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Path to FDA Approval: Analyst Recommends 'Buy' Following Positive Phase II Results and Strategic Advancements
Leerink Partners
$23
Buy
272.17%
Upside
Reiterated
02/26/25
Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)
Mizuho Securities
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Pipeline and Strategic Focus Justify Buy Rating
Jefferies
$28
Buy
353.07%
Upside
Assigned
01/22/25
Kura Oncology (KURA) Gets a Buy from Jefferies
Brookline Capital Markets
$35→$40
Buy
547.25%
Upside
Reiterated
01/06/25
Kura Oncology (KURA) PT Raised to $40 at Brookline Capital MarketsBrookline Capital Markets analyst Leah Rush Cann raised the price target on Kura Oncology (NASDAQ: KURA) to $40.00 (from $35.00) while maintaining a Buy rating.
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
JMP Securities
Reiterated
04/09/25
LifeSci Capital
Reiterated
04/08/25
H.C. Wainwright
Reiterated
04/08/25
BTIG
Reiterated
02/27/25
Scotiabank
Reiterated
02/27/25
Stifel Nicolaus
Reiterated
02/27/25
Wedbush
Reiterated
02/27/25
Barclays
Reiterated
02/27/25
Bank of America Securities
Reiterated
02/26/25
TD Cowen
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Path to FDA Approval: Analyst Recommends 'Buy' Following Positive Phase II Results and Strategic Advancements
Leerink Partners
$23
Buy
272.17%
Upside
Reiterated
02/26/25
Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)
Mizuho Securities
―
Buy
―
Reiterated
02/26/25
Kura Oncology's Promising Pipeline and Strategic Focus Justify Buy Rating
Jefferies
$28
Buy
353.07%
Upside
Assigned
01/22/25
Kura Oncology (KURA) Gets a Buy from Jefferies
Brookline Capital Markets
$35→$40
Buy
547.25%
Upside
Reiterated
01/06/25
Kura Oncology (KURA) PT Raised to $40 at Brookline Capital MarketsBrookline Capital Markets analyst Leah Rush Cann raised the price target on Kura Oncology (NASDAQ: KURA) to $40.00 (from $35.00) while maintaining a Buy rating.
Best Analysts Covering Kura Oncology
Which Analyst Should I Follow If I Want to Buy KURA and Sell After:
1 Month
xxx
Success Rate
12/17 ratings generated profit
Average Return
+0.54%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +0.54% per trade.
3 Months
xxx
Success Rate
25/43 ratings generated profit
Average Return
+10.92%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.14% of your transactions generating a profit, with an average return of +10.92% per trade.
1 Year
Success Rate
17/43 ratings generated profit
Average Return
+17.55%
reiterated a buy rating 4 months ago
Copying Leah R. Cann's trades and holding each position for 1 Year would result in 39.53% of your transactions generating a profit, with an average return of +17.55% per trade.
2 Years
xxx
Success Rate
22/43 ratings generated profit
Average Return
+22.91%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 51.16% of your transactions generating a profit, with an average return of +22.91% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
KURA Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
29
31
28
21
19
Buy
7
7
5
3
3
Hold
6
6
7
7
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
42
44
40
31
28
Each month's total comprises the sum of three months' worth of ratings.
KURA Financial Forecast
KURA Stock Forecast FAQ
What is KURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Kura Oncology’s 12-month average price target is 24.70.
What is KURA’s upside potential, based on the analysts’ average price target?
Kura Oncology has 299.68% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is KURA a Buy, Sell or Hold?
Kura Oncology has a consensus rating of Strong Buy which is based on 10 buy ratings, 3 hold ratings and 0 sell ratings.
What is Kura Oncology’s price target?
The average price target for Kura Oncology is 24.70. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 299.68% Increase from the current price of $6.18.
The highest analyst price target is $40.00 ,the lowest forecast is $10.00. The average price target represents 299.68% Increase from the current price of $6.18.
What do analysts say about Kura Oncology?
Kura Oncology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of KURA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.